These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2081686)

  • 41. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial.
    Burt RK; Shah SJ; Dill K; Grant T; Gheorghiade M; Schroeder J; Craig R; Hirano I; Marshall K; Ruderman E; Jovanovic B; Milanetti F; Jain S; Boyce K; Morgan A; Carr J; Barr W
    Lancet; 2011 Aug; 378(9790):498-506. PubMed ID: 21777972
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group.
    Lancet; 1991 Feb; 337(8739):441-6. PubMed ID: 1671468
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cyclophosphamide in exacerbations of multiple sclerosis. Therapeutic trial and a strategy for pilot drug studies.
    Drachman DA; Paterson PY; Schmidt RT; Spehlmann RF
    J Neurol Neurosurg Psychiatry; 1975 Jun; 38(6):592-7. PubMed ID: 1097604
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and tolerability of cyclophosphamide 'pulses' in multiple sclerosis: a prospective study in a clinical cohort.
    Portaccio E; Zipoli V; Siracusa G; Piacentini S; Sorbi S; Amato MP
    Mult Scler; 2003 Oct; 9(5):446-50. PubMed ID: 14582767
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The use of cyclophosphamide to treat multiple sclerosis.
    Myers LW
    Clin Neuropharmacol; 1987 Apr; 10(2):155-61. PubMed ID: 3332608
    [No Abstract]   [Full Text] [Related]  

  • 46. The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up.
    Reggio E; Nicoletti A; Fiorilla T; Politi G; Reggio A; Patti F
    J Neurol; 2005 Oct; 252(10):1255-61. PubMed ID: 15940386
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Pulse-dose cyclophosphamide therapy for steroid-refractory autoimmune neurological diseases].
    Watanabe T; Shimoji S; Sugiyama Y; Tsukamoto T; Yamamoto T
    Rinsho Shinkeigaku; 1995 Jun; 35(6):611-6. PubMed ID: 8521635
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Evaluation of the long term effect of mitoxantrone on neurological disability in patients with active multiple sclerosis].
    Mesaros S; Stojsavljević N; Dujmović I; Mandić E; Drulović J
    Srp Arh Celok Lek; 2004; 132(7-8):209-13. PubMed ID: 15615176
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis.
    Samijn JP; te Boekhorst PA; Mondria T; van Doorn PA; Flach HZ; van der Meché FG; Cornelissen J; Hop WC; Löwenberg B; Hintzen RQ
    J Neurol Neurosurg Psychiatry; 2006 Jan; 77(1):46-50. PubMed ID: 16361591
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis.
    Lamers KJ; Uitdehaag BM; Hommes OR; Doesburg W; Wevers RA; von Geel WJ
    J Neurol Neurosurg Psychiatry; 1988 Oct; 51(10):1334-7. PubMed ID: 2465387
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Immunosuppressive therapy of multiple sclerosis using cyclophosphamide with few side effects].
    Kornhuber HH; Mauch E
    Dtsch Med Wochenschr; 1986 Nov; 111(46):1778. PubMed ID: 3780443
    [No Abstract]   [Full Text] [Related]  

  • 52. [Immunosuppressive treatment in multiple sclerosis].
    Oliveira TV; Gorz-Reinhardt AM; Gracia CM; Bittencourt PR
    Arq Neuropsiquiatr; 1992 Sep; 50(3):295-301. PubMed ID: 1308406
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Experience with the use of cyclophosphamide in multiple sclerosis].
    Bel'man EL; Gordeev IaIa
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1977; 77(2):201-4. PubMed ID: 842238
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Immunosuppressive therapy of multiple sclerosis using cyclophosphamide and imuran. Report on 57 cases].
    Göpel W; Benkenstein H; Banzhaf M
    Dtsch Gesundheitsw; 1972 Oct; 27(41):1955-61. PubMed ID: 4637249
    [No Abstract]   [Full Text] [Related]  

  • 55. Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy.
    Khan OA; Zvartau-Hind M; Caon C; Din MU; Cochran M; Lisak D; Tselis AC; Kamholz JA; Garbern JY; Lisak RP
    Mult Scler; 2001 Jun; 7(3):185-8. PubMed ID: 11475443
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunosuppressive treatment of multiple sclerosis.
    Schweitzer SF
    J Neurosurg Nurs; 1985 Aug; 17(4):256-9. PubMed ID: 2993548
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An extremely aggressive case of Marburg's disease treated with high dose cyclophosphamide. A case report.
    Avila-Ornelas J; Labat E; Alfonso G; Serrano C; Fiorito F
    Mult Scler Relat Disord; 2019 Jun; 31():51-53. PubMed ID: 30925320
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combined therapeutic trial in multiple sclerosis: hydrocortisone hemisuccinate with cyclophosphamide or cytosine arabinoside.
    Cendrowski W
    Acta Neurol Belg; 1973; 73(4):209-19. PubMed ID: 4770124
    [No Abstract]   [Full Text] [Related]  

  • 59. [Effect of phlogenzym in long-term treatment of patients with multiple sclerosis].
    Mialovyts'ka OA
    Lik Sprava; 2003; (3-4):109-13. PubMed ID: 12889375
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunosuppressive treatment of multiple sclerosis.
    Carter JL; Rodriguez M
    Mayo Clin Proc; 1989 Jun; 64(6):664-9. PubMed ID: 2473360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.